Study links gut bacteria to cancer treatment response
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how the bacteria in your gut change during cancer treatment (and during some blood stem cell transplants). It may help researchers understand why some people respond differently and guide better future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 99 years old.
- You have a cancer diagnosis and are currently on cancer treatment, about to start treatment, or receiving a stem cell transplant for a blood-related condition.
- You are able to understand the study and give informed consent.
- You are not considered a “vulnerable adult” by the study’s rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at your gut “microbiome” (the bacteria in your intestines) while you receive high-dose chemotherapy and a stem cell transplant, or CAR-T cell therapy. Researchers hope to understand how these treatments affect the microbiome, which may relate to how well patients do.
This study looks at gut bacteria in people with colorectal cancer that has spread (metastatic). It aims to find patterns in the bacteria that may help doctors choose better treatments.
This study looks at changes in your gut bacteria (microbiome) around the time of stem cell transplant. The goal is to understand how these bacteria relate to transplant outcomes, which may help doctors improve care in the future.
This study looks at how gut bacteria and immune activity differ in normal, pre-cancer, and cancer colon tissue. It may help researchers understand what changes in the body are linked to colon growth and how they could be targeted in the future.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
This study looks at how gut bacteria (the microbiome) change during treatment for colorectal cancer that has spread or cannot be removed. Researchers hope the findings may help improve understanding of how treatment works and how to tailor care.
Hear when a new Hematopoietic and Lymphoid Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.